We are live on ! Find out more
MREO

Mereo BioPharma
MREO

16 hedge funds and large institutions have $5.21M invested in Mereo BioPharma in 2019 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

19% more capital invested

Capital invested by funds: $4.39M → $5.21M (+$826K)

0.02% less ownership

Funds ownership: 1.88% → 1.86% (-0.02%)

11% less funds holding

Funds holding: 18 → 16 (-2)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Holders
16
Holders Change
-2
Holders Change %
-11.11%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
5
Reduced
3
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BC
Birchview Capital
Vermont
+$90.7K
2
Morgan Stanley
Morgan Stanley
New York
+$39.5K
3
CL
CSS LLC
Illinois
+$3.19K
4
TRCT
Tower Research Capital (TRC)
New York
+$2.86K
5
UBS Group
UBS Group
Switzerland
+$1.35K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$90.1K
2
Primecap Management
Primecap Management
California
-$38.6K
3
CC
Cannell & Co
New York
-$26K
4
PAM
Panagora Asset Management
Massachusetts
-$20K
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$3K
Name Holding Trade Value Shares
Change 		Change in
Stake
Primecap Management
1
Primecap Management
California
$1.98M -$38.6K -12,754 -2%
BI
2
BVF Inc
California
$1.52M – – –
PA
3
Perceptive Advisors
New York
$534K – – –
Renaissance Technologies
4
Renaissance Technologies
New York
$495K -$90.1K -29,800 -15%
CL
5
CSS LLC
Illinois
$233K +$3.19K +1,055 +1%
BC
6
Birchview Capital
Vermont
$231K +$90.7K +30,000 +63%
Morgan Stanley
7
Morgan Stanley
New York
$79K +$39.5K +13,070 +98%
State Street
8
State Street
Massachusetts
$48K – – –
BCM
9
Bridgeway Capital Management
Texas
$46K -$2.28K -753 -5%
Bank of America
10
Bank of America
North Carolina
$36K – – –
TRCT
11
Tower Research Capital (TRC)
New York
$5K +$2.86K +945 +119%
UBS Group
12
UBS Group
Switzerland
$3K +$1.35K +448 +66%
Wells Fargo
13
Wells Fargo
California
$1K – – –
Rockefeller Capital Management
14
Rockefeller Capital Management
New York
$1K +$1.08K +358 New
CC
15
Cannell & Co
New York
– -$26K -11,025 Closed
PAM
16
Panagora Asset Management
Massachusetts
– -$20K -8,210 Closed
Acadian Asset Management
17
Acadian Asset Management
Massachusetts
– -$3K -1,302 Closed
VFA
18
Valeo Financial Advisors
Indiana
– +$18 +6 New

MREO Hedge Fund Activity: Q3 2019 in Review

16 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q3 2019, worth a combined $5.21M — up 19% from $4.39M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of MREO and 2 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 5 added.

The largest buyer was Birchview Capital, adding an estimated $90.7K. The largest seller was Renaissance Technologies, cutting an estimated $90.1K.

  • 16 institutional investors held Mereo BioPharma (MREO) as of Q3 2019, down from 18 in Q2 2019.
  • Funds reported $5.21M of Mereo BioPharma stock for Q3 2019, up 19% quarter-over-quarter.
  • 2 funds opened new Mereo BioPharma positions in Q3 2019 and 4 closed out, a net change of -2 holders.
  • The largest Mereo BioPharma buyer in Q3 2019 was Birchview Capital, an estimated $90.7K added.
  • The largest Mereo BioPharma seller in Q3 2019 was Renaissance Technologies, an estimated $90.1K sold.

Based on aggregated 13F filings for Q3 2019.